Nottingham-based chemical manufacturer 4D Medicine has raised £3.4 million in a Series A funding round led by Luxembourg’s Oshen Holdings. The funding was also backed by DSW Ventures, SFC Capital, Boundary Capital Partners LLP, and private angel investors.
- 4D Medicine was founded in 2020 by Phil Smith as a spin-off of Warwick and Birmingham Universities. The startup focuses on the research and commercialization of novel resorbable biomaterials and implantable medical devices.
- The firm’s product is called 4Degra; it is a biomaterial that can be recycled and has the potential to be utilized in a variety of implanted medical device applications. This photocurable resin can be cast, processed into thin films or meshes, or 3D printed at all scales, from nano to macro.
- The leading investor during the funding round is Luxembourg-based family-office Oshen Holdings, which focuses on the medtech and biotech sectors, while investing in a wide range of products, from early-stage to market-ready.
“The company is now poised to make a substantial impact in the bioresorbable medical device space. We believe that 4Degra is a real game-changer that is enabling 4D to develop novel bioresorbable medical devices with unique properties,” said Didier Cowling, Partner at Oshen Holdings.
- The raised money is going to help 4D Medicine finish pre-clinical testing on its initial product line and request FDA approval before entering the US market.
